Nocturnal subcutaneous apomorphine infusion in Parkinson's disease and restless legs syndrome. 1999

I Reuter, and C M Ellis, and K Ray Chaudhuri
Autonomic and Movement Disorder Unit, Regional Neuroscience Centre, King's College Hospital, London, UK.

OBJECTIVE Nocturnal disabilities leading to fragmented sleep arising from parkinsonian off period related complications are common, under-reported and are difficult to treat. In this study, we evaluate the use of nocturnal continuous subcutaneous overnight apomorphine infusion in Parkinson's disease and restless legs syndrome. METHODS Six parkinsonian patients and 2 patients with restless legs syndrome with nocturnal disabilities refractory to conventional oral therapy were assessed using a sleep diary while on standard treatment and during nocturnal apomorphine infusion. Three patients agreed to assessments during placebo infusion with normal saline. RESULTS Apomorphine led to a dramatic reduction of nocturnal awakenings, nocturnal off periods, pain, dystonia and nocturia in parkinsonian patients. In patients with restless legs syndrome, apomorphine reduced nocturnal discomfort, reduced leg movements and improved pain and spasm scores significantly. Placebo infusion reproduced pain, nocturnal spasms and sleep disruption. CONCLUSIONS This study suggests that overnight apomorphine infusion may be effective in overcoming refractory nocturnal disabilities in selected patients with Parkinson's disease and restless legs syndrome.

UI MeSH Term Description Entries
D007279 Injections, Subcutaneous Forceful administration under the skin of liquid medication, nutrient, or other fluid through a hollow needle piercing the skin. Subcutaneous Injections,Injection, Subcutaneous,Subcutaneous Injection
D007980 Levodopa The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. L-Dopa,3-Hydroxy-L-tyrosine,Dopaflex,Dopar,L-3,4-Dihydroxyphenylalanine,Larodopa,Levopa,3 Hydroxy L tyrosine,L 3,4 Dihydroxyphenylalanine,L Dopa
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D012148 Restless Legs Syndrome A disorder characterized by aching or burning sensations in the lower and rarely the upper extremities that occur prior to sleep or may awaken the patient from sleep. Restless Leg Syndrome,Restless Legs,Willis Ekbom Disease,Willis Ekbom Syndrome,Willis-Ekbom Disease,Willis-Ekbom Syndrome,Wittmaack Ekbom Syndrome,Wittmaack-Ekbom Syndrome,Disease, Willis Ekbom,Disease, Willis-Ekbom,Syndrome, Restless Leg,Syndrome, Willis Ekbom,Syndrome, Willis-Ekbom,Syndrome, Wittmaack Ekbom,Syndrome, Wittmaack-Ekbom
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

I Reuter, and C M Ellis, and K Ray Chaudhuri
September 2014, Movement disorders clinical practice,
I Reuter, and C M Ellis, and K Ray Chaudhuri
May 2006, Movement disorders : official journal of the Movement Disorder Society,
I Reuter, and C M Ellis, and K Ray Chaudhuri
January 2015, European neurology,
I Reuter, and C M Ellis, and K Ray Chaudhuri
July 2010, Movement disorders : official journal of the Movement Disorder Society,
I Reuter, and C M Ellis, and K Ray Chaudhuri
June 1992, The Medical journal of Australia,
I Reuter, and C M Ellis, and K Ray Chaudhuri
October 2009, Movement disorders : official journal of the Movement Disorder Society,
I Reuter, and C M Ellis, and K Ray Chaudhuri
January 2020, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova,
I Reuter, and C M Ellis, and K Ray Chaudhuri
January 2014, Parkinsonism & related disorders,
I Reuter, and C M Ellis, and K Ray Chaudhuri
May 2023, Journal of personalized medicine,
I Reuter, and C M Ellis, and K Ray Chaudhuri
April 2002, Journal of the neurological sciences,
Copied contents to your clipboard!